Fosmetpantotenate + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pantothenate Kinase-Associated Neurodegeneration
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Trial Timeline
Jul 17, 2017 → Dec 30, 2019
NCT ID
NCT03041116About Fosmetpantotenate + Placebo
Fosmetpantotenate + Placebo is a phase 3 stage product being developed by Travere Therapeutics for Pantothenate Kinase-Associated Neurodegeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT03041116. Target conditions include Pantothenate Kinase-Associated Neurodegeneration.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03041116 | Phase 3 | Terminated |